# ARDX catalysts: ARDELYX, INC. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/ardx/catalysts

> ARDELYX, INC. (ARDX) has 3 upcoming catalysts. The next is the XPHOZAH® (tenapanor) topline data readout, Feb to May 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | ARDELYX, INC. |
| Ticker | ARDX (Nasdaq) |
| SEC CIK | 1437402 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/ardx |

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| September 12, 2019 | [XPHOZAH® (tenapanor) FDA approval](https://sec-api.dev/pdufa/tenapanor) | ARDX |  | completed, approved | "NDA211801 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20190912, review_priority STANDARD; sponsor_name ARDELYX INC; product IBSRELA (TENAPANOR HYDROCHLORIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA211801%22)) |
| July 28, 2021 | [XPHOZAH® (tenapanor) complete response letter (CRL)](https://sec-api.dev/pdufa/tenapanor) | ARDX |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22213931_2024_Orig1s000OtherActionLtrs.pdf%22)) |
| October 17, 2023 | [XPHOZAH® (tenapanor) FDA approval](https://sec-api.dev/pdufa/tenapanor) | ARDX |  | completed, approved | "NDA213931 ORIG-1 (Type 10 - New Indication Submitted as Distinct NDA - Not Consolidated): submission_status AP, submission_status_date 20231017, review_priority STANDARD; sponsor_name ARDELYX INC; product XPHOZAH (TENAPANOR HYDROCHLORIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA213931%22)) |
| February 20, 2025 | [ARDELYX, INC. earnings report](https://sec-api.dev/companies/ardx/catalysts) | ARDX |  | completed | "Ardelyx Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1437402/000162828025006564/ardx-20241231xexhibit991.htm)) |
| May 1, 2025 | [ARDELYX, INC. earnings report](https://sec-api.dev/companies/ardx/catalysts) | ARDX |  | completed | "Ardelyx Reports First Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1437402/000162828025021514/ardx-20250331xexhibit991.htm)) |
| August 1, 2025 | [ARDELYX, INC. earnings report](https://sec-api.dev/companies/ardx/catalysts) | ARDX |  | completed | "Ardelyx Reports Second Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1437402/000162828025037441/ardx-20250630xexhibit991.htm)) |
| October 30, 2025 | [ARDELYX, INC. earnings report](https://sec-api.dev/companies/ardx/catalysts) | ARDX |  | completed | "Ardelyx Reports Third Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1437402/000143740225000016/ardx-20250930xexhibit991.htm)) |
| Jan 2026 | [XPHOZAH® (tenapanor) trial start](https://sec-api.dev/pdufa/tenapanor) | ARDX |  | completed | "In January 2026, we dosed the first patient in ACCEL and have initiated all pre-identified sites." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1437402/000143740226000044/ardx-20260630.htm)) |
| February 19, 2026 | [ARDELYX, INC. earnings report](https://sec-api.dev/companies/ardx/catalysts) | ARDX |  | completed | "Ardelyx Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1437402/000143740226000012/ardx-20251231xexhibit991.htm)) |
| April 30, 2026 | [ARDELYX, INC. earnings report](https://sec-api.dev/companies/ardx/catalysts) | ARDX |  | completed | "Ardelyx Reports First Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1437402/000143740226000021/ardx-20260331xexhibit991.htm)) |
| July 7, 2026 | [XPHOZAH® (tenapanor) primary completion](https://sec-api.dev/pdufa/tenapanor) | ARDX | Irritable Bowel Syndrome With Constipation (IBS-C) | completed | "NCT06553547 (4-Week, Multi-center Dose-Ranging Study for the IBS-C in Pts. 6 to <12 Yrs): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-07-07 (ACTUAL); Lead Sponsor Ardelyx." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06553547)) |
| August 6, 2026 | [ARDELYX, INC. earnings report](https://sec-api.dev/companies/ardx/catalysts) | ARDX |  | completed | "Ardelyx Reports Second Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1437402/000143740226000043/ardx-20260630xexhibit991.htm)) |
| August 20, 2026 | [XPHOZAH® (tenapanor) primary completion](https://sec-api.dev/pdufa/tenapanor) | ARDX | Irritable Bowel Syndrome With Constipation (IBS-C) | completed | "NCT05643534 (Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 Years): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-08-20 (ACTUAL); Lead Sponsor Ardelyx." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05643534)) |
| Aug to Nov 2026 | [XPHOZAH® (tenapanor) topline data readout](https://sec-api.dev/pdufa/tenapanor) | ARDX | Irritable Bowel Syndrome With Constipation (IBS-C) | scheduled | "NCT05643534 (Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 Years): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-08-20 (ACTUAL); Lead Sponsor Ardelyx." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05643534)) |
| November 3, 2026 | [ARDELYX, INC. earnings report](https://sec-api.dev/companies/ardx/catalysts) | ARDX |  | completed | "Ardelyx Reports Third Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1437402/000143740226000058/ardx-20260930xexhibit991.htm)) |
| Feb to May 2027 | [XPHOZAH® (tenapanor) topline data readout](https://sec-api.dev/pdufa/tenapanor) | ARDX | Chronic Idiopathic Constipation (CIC) | scheduled | "NCT07382167 (A 26-Wk Study to Assess Safety & Efficacy of Tenapanor for T/t of Chronic Idiopathic Constipation in Adults): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-02-26 (ESTIMATED); Lead Sponsor Ardelyx." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07382167)) |
| February 2027 | [XPHOZAH® (tenapanor) primary completion](https://sec-api.dev/pdufa/tenapanor) | ARDX | Chronic Idiopathic Constipation (CIC) | scheduled | "NCT07382167 (A 26-Wk Study to Assess Safety & Efficacy of Tenapanor for T/t of Chronic Idiopathic Constipation in Adults): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-02-26 (ESTIMATED); Lead Sponsor Ardelyx." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07382167)) |
| 2H 2027 | [XPHOZAH® (tenapanor) topline data readout](https://sec-api.dev/pdufa/tenapanor) | ARDX |  | scheduled | "The Company is on track to announce topline data in the second half of 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1437402/000143740226000058/ardx-20260930xexhibit991.htm)) |

## Drugs

- [XPHOZAH® (tenapanor)](https://sec-api.dev/pdufa/tenapanor): Irritable Bowel Syndrome With Constipation (IBS-C), Chronic Idiopathic Constipation (CIC)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/ardx/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "ARDX catalysts: ARDELYX, INC. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/ardx/catalysts

```bibtex
@misc{secapidev_companies_ardx_catalysts_20261116,
  title        = {ARDX catalysts: ARDELYX, INC. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/ardx/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_ardx_catalysts_20261116","title":"ARDX catalysts: ARDELYX, INC. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/ardx/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
